For distant NSCLC in the United States, 5-year relative survival is 6%. The PACIFIC trial reported 33.1% 5-year progression-free survival after durvalumab following chemoradiation in unresectable stage III NSCLC. Mortality risk also shifts with exposure and screening, including a 20% lung cancer mortality reduction with low-dose CT in the NLST and radon as the leading cause among US nonsmokers.
Key Takeaways
- For NSCLC distant disease, 5-year relative survival is 6% in the United States
- SCLC typically has an initial response rate to chemotherapy of 60%–70% in limited disease settings (system review ranges)
- In KEYNOTE-042, pembrolizumab improved overall survival versus chemotherapy in PD-L1–selected advanced NSCLC; median OS for CPS≥20 was 20.1 vs 13.1 months (HR ~0.69 as reported)
- Former smokers have about a 5–10 times higher risk of lung cancer than people who have never smoked
- Radon is the #2 cause of lung cancer and the leading cause among nonsmokers in the United States
- Asbestos exposure is responsible for about 4,500 deaths per year from mesothelioma and lung cancer in the United States
- In the NLST, lung cancer mortality reduction was 20% with low-dose CT (relative reduction) corresponding to 3.99 vs 5.42 deaths per 1000 person-years (values reported in trial publication)
- USPSTF recommends annual low-dose CT screening for adults aged 50–80 years with a 20 pack-year smoking history who currently smoke or quit within the past 15 years
- NCCN recommends annual low-dose CT for high-risk patients meeting equivalent criteria (50–80 years and ≥20 pack-year history, and current smokers or quit within 15 years)
- 33.1% 5-year progression-free survival with durvalumab after chemoradiation in unresectable stage III NSCLC (PACIFIC trial)
- Diesel exhaust exposure is classified as carcinogenic to humans (Group 1 by IARC)
Lung cancer survival varies widely, but screening, targeted therapies, and early treatment can markedly improve outcomes.
Related reading
01 · Category
Treatment & Outcomes11 stats
01
For NSCLC distant disease, 5-year relative survival is 6% in the United States
02
SCLC typically has an initial response rate to chemotherapy of 60%–70% in limited disease settings (system review ranges)
03
In KEYNOTE-042, pembrolizumab improved overall survival versus chemotherapy in PD-L1–selected advanced NSCLC; median OS for CPS≥20 was 20.1 vs 13.1 months (HR ~0.69 as reported)
04
In KEYNOTE-024, pembrolizumab vs chemotherapy in previously untreated advanced NSCLC with PD-L1≥50 increased median overall survival to 30.0 vs 14.2 months
05
In PACIFIC, 5-year progression-free survival was 33.1% with durvalumab (vs 19.5% with placebo)
06
In CheckMate 816, neoadjuvant nivolumab + chemotherapy (vs chemotherapy alone) improved pathologic complete response rate to 24% vs 2% in resectable stage IB–IIIA NSCLC
07
In ALEX, alectinib achieved 5-year progression-free survival of 39.4% (vs 27.3% for crizotinib) in untreated ALK-positive advanced NSCLC
08
In ADAURA, adjuvant osimertinib improved 5-year overall survival to 88% for resected stage IB–IIIA EGFR-mutated NSCLC
09
In FLAURA, 5-year overall survival was 47% with osimertinib vs 35% with standard EGFR TKIs in EGFR-mutated advanced NSCLC
10
In EGFR-mutated advanced NSCLC from FLAURA, median progression-free survival was 18.9 months with osimertinib
11
In IMpower010 (atezolizumab after adjuvant chemotherapy for resected stage II–IIIA NSCLC), disease-free survival benefit was reported with 1-year landmark: 85% vs 76% (reported hazard ratio ~0.66 for PD-L1≥1%)
Interpretation
Treatment & Outcomes Interpretation
Under the Treatment & Outcomes angle, advances in therapy show measurable gains such as 5 year progression free survival reaching 33.1% with durvalumab in PACIFIC compared with 19.5% on placebo, even though distant NSCLC outcomes in the US remain very low at a 6% 5 year relative survival rate.
02 · Category
Disparities And Risk4 stats
01
Former smokers have about a 5–10 times higher risk of lung cancer than people who have never smoked
02
Radon is the #2 cause of lung cancer and the leading cause among nonsmokers in the United States
03
Asbestos exposure is responsible for about 4,500 deaths per year from mesothelioma and lung cancer in the United States
04
About 15% of lung cancer deaths occur among people who have never smoked
Interpretation
Disparities And Risk Interpretation
Under the Disparities And Risk lens, lung cancer risk is far from equal because former smokers face about 5–10 times the risk of never smokers, radon is the #2 cause of lung cancer and the leading cause among nonsmokers, and even about 15% of lung cancer deaths occur in people who have never smoked.
03 · Category
Screening & Early Detection7 stats
01
In the NLST, lung cancer mortality reduction was 20% with low-dose CT (relative reduction) corresponding to 3.99 vs 5.42 deaths per 1000 person-years (values reported in trial publication)
02
USPSTF recommends annual low-dose CT screening for adults aged 50–80 years with a 20 pack-year smoking history who currently smoke or quit within the past 15 years
03
NCCN recommends annual low-dose CT for high-risk patients meeting equivalent criteria (50–80 years and ≥20 pack-year history, and current smokers or quit within 15 years)
04
In the PLCO trial, 5-year lung cancer mortality was not reduced by screening with chest X-ray (rate ratios ~1.0 reported)
05
The median follow-up in NELSON long-term results was 10 years for mortality analysis
06
In the 2023 US lung cancer screening uptake analyses, low-dose CT screening use among eligible adults increased to 8.0% (as reported in published US claims-based analyses)
07
In the 2015–2017 US period, lung cancer screening eligibility prevalence among current/former smokers was about 20 million adults (as estimated in CDC surveillance summaries)
Interpretation
Screening & Early Detection Interpretation
Across major screening studies and guidelines, low-dose CT stands out for early detection, cutting lung cancer mortality by about 20% in the NLST while eligible uptake in 2023 still reached only 8.0%, highlighting both the benefit of screening and the ongoing need to close the gap.
More related reading
04 · Category
Treatment Outcomes1 stats
01
33.1% 5-year progression-free survival with durvalumab after chemoradiation in unresectable stage III NSCLC (PACIFIC trial)
Interpretation
Treatment Outcomes Interpretation
In treatment outcomes for unresectable stage III NSCLC, durvalumab given after chemoradiation showed a 33.1% 5-year progression-free survival rate, indicating a meaningful long-term benefit within this treatment-focused category.
05 · Category
Risk Factors1 stats
01
Diesel exhaust exposure is classified as carcinogenic to humans (Group 1 by IARC)
Interpretation
Risk Factors Interpretation
As a key risk factor, diesel exhaust exposure is classified as carcinogenic to humans by IARC in Group 1, underscoring a well established link between this exposure and lung cancer.
report visual · Breakdown
Lung cancer outcomes: survival highlights
Key trials and population data show markedly different survival and progression-free outcomes across settings and treatments.
85%
In IMpower010 (atezolizumab after adjuvant chemotherapy for resected stage II–IIIA NSCLC), disease-free survival benefit
15%
About 15% of lung cancer deaths occur among people who have never smoked
source-verifiednejm.org · cancer.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lukas Bauer. (2026, February 13). Lung Cancer Survival Rate Statistics. Gitnux. https://gitnux.org/lung-cancer-survival-rate-statistics
MLA
Lukas Bauer. "Lung Cancer Survival Rate Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/lung-cancer-survival-rate-statistics.
Chicago
Lukas Bauer. 2026. "Lung Cancer Survival Rate Statistics." Gitnux. https://gitnux.org/lung-cancer-survival-rate-statistics.
Sources & references
24 datasets cited across this report · attribution is report-level
+13 additional datasets cited (not shown individually)